Objective: Benign familial infantile epilepsy (BFIE) is an autosomal dominant epilepsy syndrome characterized by afebrile seizures beginning at about 6 months of age. Mutations in PRRT2, encoding the proline-rich transmembrane protein 2 gene, have recently been identified in the majority of families with BFIE and the associated syndrome of infantile convulsions and choreoathetosis (ICCA). We asked whether the phenotypic spectrum of PRRT2 was broader than initially recognized by studying patients with sporadic benign infantile seizures and non-BFIE familial infantile seizures for PRRT2 mutations.
Mutations in the proline-rich transmembrane protein 2 gene (PRRT2) have recently been found to cause approximately 80% of 2 autosomal dominant infantile-onset seizure disorders, benign familial infantile epilepsy (BFIE) and infantile convulsions choreoathetosis (ICCA) syndrome, 1,2 following the discovery of PRRT2 mutations in autosomal dominant paroxysmal kinesigenic dyskinesia (PKD). [3] [4] [5] [6] A variety of mutations in PRRT2 have been reported, with the most common mutation in all 3 disorders being the c.649-650insC (p.R217fsX224) frameshift mutation.
In BFIE (MIM 605751), seizures begin in a normal infant at a mean age of 6 months and typically cease by 2 years. Seizures commonly comprise clusters of focal or convulsive attacks. Interictal EEG and MRI studies are usually normal. [7] [8] [9] In ICCA (MIM 602066), family members have either infantile seizures or child/ adolescent onset paroxysmal kinesigenic dyskinesia (PKD) 10 (MIM 128200), or both.
Here we ask whether the phenotypic spectrum of PRRT2 mutations extends beyond BFIE and ICCA. In addition to expanding our published cohort of classical BFIE and ICCA, we studied individuals with sporadic benign infantile seizures and families with atypical features for BFIE such as later seizure onset or offset, more severe seizures (such as episodes of status epilepticus), and multiple seizure types. We also investigated sporadic and familial benign neonatal seizures and infantile convulsions with mild gastroenteritis. [11] [12] [13] METHODS Individuals and families with infantile-onset seizure disorders were recruited from pediatric epilepsy and neurology clinics and by referral to the investigators over a 20-year period. All affected individuals underwent detailed electroclinical assessment including a validated seizure questionnaire. 14 In particular, seizure-related triggers such as the presence of fever, gastroenteritis, and viral illnesses were examined. A careful history for movement disorders was also noted in the proband and family members. Where a family history of seizures or movement disorders was present, all available affected family members were phenotyped.
Standard protocol approvals, registrations, and patient consents. Molecular analysis of the PRRT2 gene. The open reading frame of PRRT2 (NM_145239.2) was analyzed by direct Sanger sequencing of genomic DNA from each proband. Family members were then analyzed for the c.649-650insC mutation by direct sequencing or by amplification using the labeled primers 59-HEX-TCACTCACCACCCTCAAA-39 and 59-CATTC-GATCCTCCTCAAC-39, followed by separation of the products by capillary electrophoresis on the ABI 3131 genetic analyzer. For the latter assay, normal samples have a single peak at 85 bp while the insertion mutation is detected as a double peak. The primer sequences used for mutation screening are listed in appendix e-1 on the Neurology ® Web site at www.neurology.org.
RESULTS
Of the 44 probands, 30 had infantile onset seizures, 5 had convulsions with mild gastroenteritis between 8 months and 3 years, and 9 had neonatal onset seizures (phenotypes listed in the table and the figure) .
PRRT2 mutations were identified in 11 probands: 4 had a family history consistent with BFIE, 5 with ICCA, and 2 had no family history of infantile seizures or PKD (figure). The 11 mutation-positive probands all had the common PRRT2 frameshift mutation, c.649-650insC (p.R217fsX224). Each sporadic case was confirmed to have a de novo mutation that was absent in their parents. Although families A and E were otherwise typical, 4 individuals had seizures with and without fever and were initially classified as febrile seizures plus. 15 Family E also had 4 individuals with febrile seizures, of which 2 had the PRRT2 mutation. One phenocopy was observed (family C) and 3 nonpenetrant carriers (families A, B, and C).
Nineteen of the 44 probands had a family history of seizures, but the familial pattern fell outside BFIE or ICCA due to a more severe seizure course than expected in BFIE such as seizures continuing into childhood, episodes of status epilepticus, more frequent seizures than typically seen in BFIE, later onset seizures, or multiple seizure types in the relatives (table). None had PRRT2 mutations.
No PRRT2 mutations were found in 5 probands with convulsions with mild gastroenteritis nor in 9 probands with benign neonatal seizures where no other molecular cause was found.
DISCUSSION PRRT2 mutations are found in more than 90% of ICCA families and 80% of families with BFIE, in addition to 89% of families with autosomal dominant PKD, illustrating the pleiotropic phenotypic expression of PRRT2. Here, we sought to expand the phenotypic spectrum associated with PRRT2 mutations by examining other familial and sporadic infantile-onset seizures.
We found that 2 boys with sporadic benign infantile seizures had the common PRRT2 mutation which was shown to have arisen de novo rather than having been inherited from a parent. This highlights that isolated as well as familial cases of benign infantile epilepsy can be due to mutations in PRRT2. De novo mutations were suspected to contribute to benign infantile epilepsy due to the many independent mutational events in the PRRT2 gene which have thus far been reported across many ethnicities, with the frameshift mutation p.R217fsX224 accounting for the majority of these events. This common mutation inserts an additional cytosine (C) in a homopolymer of 9 cytosines, creating a hairpin loop predicted to cause DNA polymerase slippage and resulting in a mutation "hotspot." 2 Probands with sporadic benign infantile seizures and BFIE may be clinically indistinguishable [16] [17] [18] and PRRT2 mutations should be considered in sporadic cases as they carry genetic counseling and prognostic implications. A further issue with diagnosis of ICCA is the subtlety of the family history of PKD. The history of PKD in relatives was often not recognized or considered related to the seizures in infants at presentation. It was only ascertained by specific questioning, often allowing treatment for symptoms that had been present over many years and had affected daily life in adults with PKD who had not sought medical treatment.
We identified mutations in 4/6 new families with BFIE and 5/5 new families with ICCA. Thus, taken together with the families we previously reported, we have detected PRRT2 mutations in 18/23 (78%) BFIE and 10/11 (91%) ICCA families of our cohort. 2 Interestingly, although BFIE and ICCA classically comprise afebrile seizures in infancy, we observed 8 individuals from 3 families with PRRT2 mutations who had phenotypes that were considered to be febrile seizures (FS) or febrile seizures plus (FS1) (families A and E; individual 16-II-2 in reference 2). FS1 is defined by FS that continue past the age of 6 years or where afebrile convulsions occur with FS. It is one of the phenotypes that form part of the familial epilepsy syndrome of genetic epilepsy with FS plus (GEFS1). 19 When we reported family E as family CL in 1999, 15 we described 2 individuals as FS1 and 4 as FS. The finding that 5 of these family members have the PRRT2 mutation suggests that additional FS genes exist in this family. As FS or FS1 may begin in the first year with offset in early childhood, these phenotypes overlap with BFIE if fever is present. Thus BFIE is a differential diagnosis in certain families with FS and FS1 under 2 years of age that may have been conceptualized as GEFS1 families, and mutational analysis of PRRT2 should be considered. In smaller families with only a few affected individuals, this distinction may be even more difficult. Modifier genes may explain the predisposition to seizures with fever in these PRRT2 families with evidence for additional genetic variants being present in family E and family 16 2 where members not carrying the familial PRRT2 mutation had FS. As 6 cases from 5 of our PRRT2 BFIE and ICCA families had some or all of their seizures with gastroenteritis, we examined 5 additional patients with convulsions with mild gastroenteritis, an increasingly recognized syndrome. 12, 13 None had PRRT2 mutations. Our findings suggest that BFIE and sporadic cases of convulsions with gastroenteritis have distinct causes.
No PRRT2 mutations were identified in families with "atypical" infantile seizures or probands with a family history of later onset seizures. We included 19 with infantile seizures falling outside the BFIE phenotype so it is possible that testing larger cohorts of patients will reveal mutations in novel phenotypes. Given the referral bias to our study of epilepsy genetics, it is unlikely that we would be biased against those with PRRT2 mutations as we are more likely to ascertain those cases with a family history. As both of our 2 infants with "sporadic" self-limited infantile seizures had de novo PRRT2 mutations, a key question is the importance of PRRT2 in a large cohort of similar cases.
Previously, overlap has been demonstrated between the ages at seizure onset in families with BFIE and benign familial neonatal seizures. We therefore studied babies with sporadic and benign familial neonatal seizures not associated with potassium channel mutations in KCNQ2 and KCNQ3, but no PRRT2 mutations were identified. These observations suggest that PRRT2 is associated with a specific self-limited, age-dependent epilepsy syndrome likely relating to developmental expression and function of the PRRT2 protein.
As little is known about the function of PRRT2 it is difficult to hypothesize how the same mutation of this gene can cause both epilepsy and a movement disorder either in the same individual or family, or in separate families. Here, the number of probands tested was relatively small so a definitive statement regarding lack of involvement of PRRT2 in specific phenotypes cannot be made. There is, however, a striking difference between the high mutation rate in BFIE and ICCA and the absence of mutations in other phenotypes, showing that PRRT2 is not a frequent cause of these additional phenotypes.
Confirmation of PRRT2 mutations in patients with infantile seizures provides families and clinicians with reassurance that the seizures are likely to be selflimited with an excellent outcome. Families can also be forewarned about the possibility of paroxysmal kinesigenic dyskinesia developing later in childhood or adolescence to enable rapid diagnosis and appropriate treatment. 
